Sera Prognostics Innovates Maternal Health with New Testing and Awareness Initiatives

Sera Prognostics Drives Innovation in Maternal Health with New Initiatives

Sera Prognostics Inc., recognized as The Pregnancy Company®, is making significant strides in enhancing maternal and neonatal health through its innovative approaches. The company reports a revenue of $29,000 for the third quarter of 2024, reflecting its commitment to developing pregnancy biomarker information that informs clinical interventions. Recently, Sera has embarked on a comprehensive data analysis of its Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal Outcomes (PRIME) study. The anticipation surrounding the publication of these findings in early 2025 at major health conferences and peer-reviewed journals underscores Sera's dedication to advancing scientific knowledge in maternal health.

In addition to its research efforts, Sera Prognostics is focused on increasing public awareness of its groundbreaking test-and-treat offerings. The company has launched a promotional campaign featuring well-known personalities Dennis Quaid and Meg Ryan, aiming to reach over 84 million households across the United States. This initiative not only highlights the importance of Sera’s PreTRM® testing but also seeks to educate expectant mothers about available resources for their prenatal care. By fostering greater awareness, Sera aims to drive consumer engagement and ultimately increase test adoption among pregnant women.

To further enhance accessibility and convenience, Sera has recently enabled online access to its PreTRM® testing, allowing expectant mothers to collect home samples and receive results to discuss with their healthcare providers. This strategic move aims to empower consumers to take proactive steps in understanding their pregnancy risks. Additionally, Sera is beta testing a predictive analytics tool designed to offer personalized insights based on extensive data from past pregnancies. The recent transition to ambient whole blood collection not only improves access to PreTRM testing but also reduces costs and increases laboratory capacity, positioning Sera for a potential commercial breakthrough in the maternal care market. CEO Zhenya Lindgardt emphasizes that these initiatives are crucial for achieving commercial success and anticipates a sales inflection that will accompany growth in margins and revenue.

As Sera Prognostics continues to innovate and expand its offerings, the company's commitment to improving maternal and neonatal health remains at the forefront. With a strengthened commercial team and a focus on enhancing the customer experience, Sera is poised to make a lasting impact in the field of maternal care. The combination of research advancements, public awareness campaigns, and improved access to testing positions Sera as a leader in the pregnancy health industry, dedicated to providing expectant mothers with the insights they need for healthier pregnancies.